You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
邁克生物(300463.SZ)擬設立參股公司 推動“國家精準醫學產業創新中心”建設和運營
格隆匯 12-03 19:28

格隆匯12月3日丨邁克生物(300463.SZ)公佈,公司於2019年12月02日與成都利康實業有限責任公司(系四川大學華西醫院全資子公司)、上海醫藥集團股份有限公司、成都高新投資集團有限公司、成都科技服務集團有限公司、四川希氏異構醫療科技有限公司、成都華西海圻醫藥科技有限公司簽署了《成都華西精準醫學產業創新中心有限公司出資人協議書》(“《出資人協議書》”),擬在成都市高新區共建“國家精準醫學產業創新中心”,並共同出資設立成都華西精準醫學產業創新中心有限公司(“合資公司”)運營該中心。合資公司註冊資本5億元,邁克生物佔合資公司註冊資本的10%。合資公司已於2019年12月2日取得成都高新技術產業開發區市場監督管理局頒發的營業執照。

成都華西精準醫學產業創新中心有限公司經營範圍:生物技術、醫藥技術(不含醫療衞生活動)、基因工程技術、細胞工程技術、醫療器械、人工智能技術、計算機技術研究、技術推廣、技術轉讓、技術諮詢、技術服務;醫學研究和試驗發展;其他技術推廣服務;科技中介服務。(依法須經批准的項目,經相關部門批准後方可開展經營活動)

公司此次參與投資設立的合資公司,將藉助四川大學華西醫院的科研技術和廣泛醫療資源,股東單位發揮各自資源、人才和技術等優勢,推動“國家精準醫學產業創新中心”的建設和運營。精準醫學產業涵蓋分子診斷、細胞治療、靶向藥物、醫學人工智能、生物醫學材料、創新醫療器械等多平台,此次投資將有助於公司對標國際前沿技術方向,促進公司在分子診斷平台的技術創新和成果轉移轉化,為公司佈局精準醫療領域的戰略規劃建立良好的基礎。

通過此次投資,公司將參與到精準醫學產業鏈上中下游的資源整合中,可以增強產學研合作和臨牀資源獲取,加快研發成果轉化和產業化進程,對公司未來發展產生積極作用。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account